HC Wainwright Comments on ACADIA Pharmaceuticals Inc.’s FY2027 Earnings (NASDAQ:ACAD)

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Rating) – HC Wainwright issued their FY2027 earnings per share estimates for shares of ACADIA Pharmaceuticals in a report released on Tuesday, February 28th. HC Wainwright analyst A. Fein forecasts that the biopharmaceutical company will earn $1.81 per share for the year. HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is ($0.99) per share.

Several other analysts also recently weighed in on the company. Citigroup increased their target price on ACADIA Pharmaceuticals from $19.00 to $19.40 and gave the company a “neutral” rating in a research note on Tuesday. Guggenheim upgraded ACADIA Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $22.00 price objective for the company in a research report on Tuesday, January 3rd. The Goldman Sachs Group downgraded ACADIA Pharmaceuticals from a “neutral” rating to a “sell” rating and reduced their price objective for the stock from $15.00 to $12.00 in a research report on Thursday, November 3rd. Mizuho raised their price objective on ACADIA Pharmaceuticals from $15.00 to $19.00 and gave the stock a “neutral” rating in a research report on Tuesday. Finally, JMP Securities reduced their price objective on ACADIA Pharmaceuticals from $24.00 to $22.00 and set a “market perform” rating for the company in a research report on Tuesday. Two analysts have rated the stock with a sell rating, six have issued a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, ACADIA Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $20.52.

ACADIA Pharmaceuticals Stock Performance

ACAD opened at $20.92 on Wednesday. The company has a market cap of $3.39 billion, a PE ratio of -15.61 and a beta of 0.64. The stock has a 50-day moving average of $18.25 and a 200-day moving average of $16.87. ACADIA Pharmaceuticals has a 52-week low of $12.24 and a 52-week high of $28.06.

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Rating) last released its quarterly earnings results on Monday, February 27th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.01). The company had revenue of $136.49 million for the quarter, compared to the consensus estimate of $135.18 million. ACADIA Pharmaceuticals had a negative return on equity of 49.64% and a negative net margin of 41.76%. The business’s revenue was up 4.4% compared to the same quarter last year. During the same quarter last year, the company posted ($0.27) EPS.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of ACAD. Healthcare of Ontario Pension Plan Trust Fund bought a new position in ACADIA Pharmaceuticals in the 2nd quarter valued at $2,432,000. Nordea Investment Management AB boosted its position in ACADIA Pharmaceuticals by 1.7% in the 2nd quarter. Nordea Investment Management AB now owns 630,080 shares of the biopharmaceutical company’s stock valued at $8,890,000 after buying an additional 10,555 shares during the last quarter. Bain Capital Life Sciences Investors LLC boosted its position in ACADIA Pharmaceuticals by 1.7% in the 3rd quarter. Bain Capital Life Sciences Investors LLC now owns 610,523 shares of the biopharmaceutical company’s stock valued at $9,988,000 after buying an additional 10,000 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its position in ACADIA Pharmaceuticals by 1.1% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 200,032 shares of the biopharmaceutical company’s stock valued at $3,273,000 after buying an additional 2,117 shares during the last quarter. Finally, Cubist Systematic Strategies LLC boosted its position in ACADIA Pharmaceuticals by 268.9% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 102,825 shares of the biopharmaceutical company’s stock valued at $1,682,000 after buying an additional 74,952 shares during the last quarter. 92.79% of the stock is owned by institutional investors and hedge funds.

Insider Activity at ACADIA Pharmaceuticals

In related news, CEO Stephen Davis sold 3,904 shares of the firm’s stock in a transaction on Monday, January 9th. The stock was sold at an average price of $17.13, for a total transaction of $66,875.52. Following the completion of the sale, the chief executive officer now directly owns 84,633 shares of the company’s stock, valued at approximately $1,449,763.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Stephen Davis sold 3,904 shares of the firm’s stock in a transaction on Monday, January 9th. The stock was sold at an average price of $17.13, for a total transaction of $66,875.52. Following the completion of the sale, the chief executive officer now directly owns 84,633 shares of the company’s stock, valued at approximately $1,449,763.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Laura Brege sold 12,500 shares of the firm’s stock in a transaction on Thursday, January 12th. The shares were sold at an average price of $18.25, for a total value of $228,125.00. The disclosure for this sale can be found here. Insiders sold 23,567 shares of company stock valued at $427,672 in the last three months. Corporate insiders own 28.40% of the company’s stock.

About ACADIA Pharmaceuticals

(Get Rating)

ACADIA Pharmaceuticals, Inc operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm’s products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.